Post-kala-azar dermal leishmaniasis

Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. The rash usually starts around the mouth from where it spreads to other par...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2003-02, Vol.3 (2), p.87-98
Hauptverfasser: Zijlstra, EE, Musa, AM, Khalil, EAG, El Hassan, IM, El-Hassan, AM
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 98
container_issue 2
container_start_page 87
container_title The Lancet infectious diseases
container_volume 3
creator Zijlstra, EE
Musa, AM
Khalil, EAG
El Hassan, IM
El-Hassan, AM
description Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. The rash usually starts around the mouth from where it spreads to other parts of the body depending on severity. It is mainly seen in Sudan and India where it follows treated VL in 50% and 5–10% of cases, respectively. Thus, it is largely restricted to areas where Leishmania donovani is the causative parasite. The interval at which PKDL follows VL is 0–6 months in Sudan and 2–3 years in India. PKDL probably has an important role in interepidemic periods of VL, acting as a reservoir for parasites. There is increasing evidence that the pathogenesis is largely immunologically mediated; high concentrations of interleukin 10 in the peripheral blood of VL patients predict the development of PKDL. During VL, interferon γ is not produced by peripheral blood mononuclear cells (PBMC). After treatment of VL, PBMC start producing interferon γ, which coincides with the appearance of PKDL lesions due to interferon-γ-producing cells causing skin inflammation as a reaction to persisting parasites in the skin. Diagnosis is mainly clinical, but parasites can be seen by microscopy in smears with limited sensitivity. PCR and monoclonal antibodies may detect parasites in more than 80% of cases. Serological tests and the leishmanin skin test are of limited value. Treatment is always needed in Indian PKDL; in Sudan most cases will self cure but severe and chronic cases are treated. Sodium stibogluconate is given at 20 mg/kg for 2 months in Sudan and for 4 months in India. Liposomal amphotericine B seems effective; newer compounds such as miltefosine that can be administered orally or topically are of major potential interest. Although research has brought many new insights in pathogenesis and management of PKDL, several issues in particular in relation to control remain unsolved and deserve urgent attention.
doi_str_mv 10.1016/S1473-3099(03)00517-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72985812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309903005176</els_id><sourcerecordid>72985812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-c6a88a0f09cd95487a9267cdeef64acd42355d152c1b225da4bf2818743e1ac83</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMoVqs_QSkKoofVTD42yUmk-AUFBfUc0iSLqbvdmuwK-uvddguCl55mGJ53hnkQOgJ8CRjyqxdggmYUK3WO6QXGHESWb6G9bswyxrjYXvU9MkD7Kc0wBgGY7aIBEJ5jUGwPnT7Xqck-TGky82PiyPlYmXJU-pDeKzMPJoV0gHYKUyZ_uK5D9HZ3-zp-yCZP94_jm0lmmYAms7mR0uACK-sUZ1IYRXJhnfdFzox1jFDOHXBiYUoId4ZNCyJBCkY9GCvpEJ31exex_mx9anQVkvVlaea-bpMWREkugWwEQRFCsFiCJ__AWd3GefeEJhg4p0TRDuI9ZGOdUvSFXsRQmfitAeula71yrZciNaZ65VrnXe54vbydVt79pdZyO-C6B3wn7Sv4qJMNfm69C9HbRrs6bDjxC5Ihi4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201553293</pqid></control><display><type>article</type><title>Post-kala-azar dermal leishmaniasis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Zijlstra, EE ; Musa, AM ; Khalil, EAG ; El Hassan, IM ; El-Hassan, AM</creator><creatorcontrib>Zijlstra, EE ; Musa, AM ; Khalil, EAG ; El Hassan, IM ; El-Hassan, AM</creatorcontrib><description>Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. The rash usually starts around the mouth from where it spreads to other parts of the body depending on severity. It is mainly seen in Sudan and India where it follows treated VL in 50% and 5–10% of cases, respectively. Thus, it is largely restricted to areas where Leishmania donovani is the causative parasite. The interval at which PKDL follows VL is 0–6 months in Sudan and 2–3 years in India. PKDL probably has an important role in interepidemic periods of VL, acting as a reservoir for parasites. There is increasing evidence that the pathogenesis is largely immunologically mediated; high concentrations of interleukin 10 in the peripheral blood of VL patients predict the development of PKDL. During VL, interferon γ is not produced by peripheral blood mononuclear cells (PBMC). After treatment of VL, PBMC start producing interferon γ, which coincides with the appearance of PKDL lesions due to interferon-γ-producing cells causing skin inflammation as a reaction to persisting parasites in the skin. Diagnosis is mainly clinical, but parasites can be seen by microscopy in smears with limited sensitivity. PCR and monoclonal antibodies may detect parasites in more than 80% of cases. Serological tests and the leishmanin skin test are of limited value. Treatment is always needed in Indian PKDL; in Sudan most cases will self cure but severe and chronic cases are treated. Sodium stibogluconate is given at 20 mg/kg for 2 months in Sudan and for 4 months in India. Liposomal amphotericine B seems effective; newer compounds such as miltefosine that can be administered orally or topically are of major potential interest. Although research has brought many new insights in pathogenesis and management of PKDL, several issues in particular in relation to control remain unsolved and deserve urgent attention.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(03)00517-6</identifier><identifier>PMID: 12560194</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Africa, Eastern - epidemiology ; amphotericin B ; Asia - epidemiology ; Humans ; India - epidemiology ; Infectious diseases ; interleukin 10 ; Leishmania donovani ; Leishmaniasis, Cutaneous - diagnosis ; Leishmaniasis, Cutaneous - epidemiology ; Leishmaniasis, Cutaneous - physiopathology ; Leishmaniasis, Cutaneous - therapy ; Leishmaniasis, Visceral - diagnosis ; Leishmaniasis, Visceral - epidemiology ; Leishmaniasis, Visceral - physiopathology ; Leishmaniasis, Visceral - therapy ; miltefosine ; Parasites ; sodium stibogluconate ; Sudan - epidemiology ; Vector-borne diseases</subject><ispartof>The Lancet infectious diseases, 2003-02, Vol.3 (2), p.87-98</ispartof><rights>2003 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Feb 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-c6a88a0f09cd95487a9267cdeef64acd42355d152c1b225da4bf2818743e1ac83</citedby><cites>FETCH-LOGICAL-c471t-c6a88a0f09cd95487a9267cdeef64acd42355d152c1b225da4bf2818743e1ac83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/201553293?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12560194$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zijlstra, EE</creatorcontrib><creatorcontrib>Musa, AM</creatorcontrib><creatorcontrib>Khalil, EAG</creatorcontrib><creatorcontrib>El Hassan, IM</creatorcontrib><creatorcontrib>El-Hassan, AM</creatorcontrib><title>Post-kala-azar dermal leishmaniasis</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. The rash usually starts around the mouth from where it spreads to other parts of the body depending on severity. It is mainly seen in Sudan and India where it follows treated VL in 50% and 5–10% of cases, respectively. Thus, it is largely restricted to areas where Leishmania donovani is the causative parasite. The interval at which PKDL follows VL is 0–6 months in Sudan and 2–3 years in India. PKDL probably has an important role in interepidemic periods of VL, acting as a reservoir for parasites. There is increasing evidence that the pathogenesis is largely immunologically mediated; high concentrations of interleukin 10 in the peripheral blood of VL patients predict the development of PKDL. During VL, interferon γ is not produced by peripheral blood mononuclear cells (PBMC). After treatment of VL, PBMC start producing interferon γ, which coincides with the appearance of PKDL lesions due to interferon-γ-producing cells causing skin inflammation as a reaction to persisting parasites in the skin. Diagnosis is mainly clinical, but parasites can be seen by microscopy in smears with limited sensitivity. PCR and monoclonal antibodies may detect parasites in more than 80% of cases. Serological tests and the leishmanin skin test are of limited value. Treatment is always needed in Indian PKDL; in Sudan most cases will self cure but severe and chronic cases are treated. Sodium stibogluconate is given at 20 mg/kg for 2 months in Sudan and for 4 months in India. Liposomal amphotericine B seems effective; newer compounds such as miltefosine that can be administered orally or topically are of major potential interest. Although research has brought many new insights in pathogenesis and management of PKDL, several issues in particular in relation to control remain unsolved and deserve urgent attention.</description><subject>Africa, Eastern - epidemiology</subject><subject>amphotericin B</subject><subject>Asia - epidemiology</subject><subject>Humans</subject><subject>India - epidemiology</subject><subject>Infectious diseases</subject><subject>interleukin 10</subject><subject>Leishmania donovani</subject><subject>Leishmaniasis, Cutaneous - diagnosis</subject><subject>Leishmaniasis, Cutaneous - epidemiology</subject><subject>Leishmaniasis, Cutaneous - physiopathology</subject><subject>Leishmaniasis, Cutaneous - therapy</subject><subject>Leishmaniasis, Visceral - diagnosis</subject><subject>Leishmaniasis, Visceral - epidemiology</subject><subject>Leishmaniasis, Visceral - physiopathology</subject><subject>Leishmaniasis, Visceral - therapy</subject><subject>miltefosine</subject><subject>Parasites</subject><subject>sodium stibogluconate</subject><subject>Sudan - epidemiology</subject><subject>Vector-borne diseases</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkE1LAzEQhoMoVqs_QSkKoofVTD42yUmk-AUFBfUc0iSLqbvdmuwK-uvddguCl55mGJ53hnkQOgJ8CRjyqxdggmYUK3WO6QXGHESWb6G9bswyxrjYXvU9MkD7Kc0wBgGY7aIBEJ5jUGwPnT7Xqck-TGky82PiyPlYmXJU-pDeKzMPJoV0gHYKUyZ_uK5D9HZ3-zp-yCZP94_jm0lmmYAms7mR0uACK-sUZ1IYRXJhnfdFzox1jFDOHXBiYUoId4ZNCyJBCkY9GCvpEJ31exex_mx9anQVkvVlaea-bpMWREkugWwEQRFCsFiCJ__AWd3GefeEJhg4p0TRDuI9ZGOdUvSFXsRQmfitAeula71yrZciNaZ65VrnXe54vbydVt79pdZyO-C6B3wn7Sv4qJMNfm69C9HbRrs6bDjxC5Ihi4w</recordid><startdate>200302</startdate><enddate>200302</enddate><creator>Zijlstra, EE</creator><creator>Musa, AM</creator><creator>Khalil, EAG</creator><creator>El Hassan, IM</creator><creator>El-Hassan, AM</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>200302</creationdate><title>Post-kala-azar dermal leishmaniasis</title><author>Zijlstra, EE ; Musa, AM ; Khalil, EAG ; El Hassan, IM ; El-Hassan, AM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-c6a88a0f09cd95487a9267cdeef64acd42355d152c1b225da4bf2818743e1ac83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Africa, Eastern - epidemiology</topic><topic>amphotericin B</topic><topic>Asia - epidemiology</topic><topic>Humans</topic><topic>India - epidemiology</topic><topic>Infectious diseases</topic><topic>interleukin 10</topic><topic>Leishmania donovani</topic><topic>Leishmaniasis, Cutaneous - diagnosis</topic><topic>Leishmaniasis, Cutaneous - epidemiology</topic><topic>Leishmaniasis, Cutaneous - physiopathology</topic><topic>Leishmaniasis, Cutaneous - therapy</topic><topic>Leishmaniasis, Visceral - diagnosis</topic><topic>Leishmaniasis, Visceral - epidemiology</topic><topic>Leishmaniasis, Visceral - physiopathology</topic><topic>Leishmaniasis, Visceral - therapy</topic><topic>miltefosine</topic><topic>Parasites</topic><topic>sodium stibogluconate</topic><topic>Sudan - epidemiology</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zijlstra, EE</creatorcontrib><creatorcontrib>Musa, AM</creatorcontrib><creatorcontrib>Khalil, EAG</creatorcontrib><creatorcontrib>El Hassan, IM</creatorcontrib><creatorcontrib>El-Hassan, AM</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zijlstra, EE</au><au>Musa, AM</au><au>Khalil, EAG</au><au>El Hassan, IM</au><au>El-Hassan, AM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Post-kala-azar dermal leishmaniasis</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2003-02</date><risdate>2003</risdate><volume>3</volume><issue>2</issue><spage>87</spage><epage>98</epage><pages>87-98</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. The rash usually starts around the mouth from where it spreads to other parts of the body depending on severity. It is mainly seen in Sudan and India where it follows treated VL in 50% and 5–10% of cases, respectively. Thus, it is largely restricted to areas where Leishmania donovani is the causative parasite. The interval at which PKDL follows VL is 0–6 months in Sudan and 2–3 years in India. PKDL probably has an important role in interepidemic periods of VL, acting as a reservoir for parasites. There is increasing evidence that the pathogenesis is largely immunologically mediated; high concentrations of interleukin 10 in the peripheral blood of VL patients predict the development of PKDL. During VL, interferon γ is not produced by peripheral blood mononuclear cells (PBMC). After treatment of VL, PBMC start producing interferon γ, which coincides with the appearance of PKDL lesions due to interferon-γ-producing cells causing skin inflammation as a reaction to persisting parasites in the skin. Diagnosis is mainly clinical, but parasites can be seen by microscopy in smears with limited sensitivity. PCR and monoclonal antibodies may detect parasites in more than 80% of cases. Serological tests and the leishmanin skin test are of limited value. Treatment is always needed in Indian PKDL; in Sudan most cases will self cure but severe and chronic cases are treated. Sodium stibogluconate is given at 20 mg/kg for 2 months in Sudan and for 4 months in India. Liposomal amphotericine B seems effective; newer compounds such as miltefosine that can be administered orally or topically are of major potential interest. Although research has brought many new insights in pathogenesis and management of PKDL, several issues in particular in relation to control remain unsolved and deserve urgent attention.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>12560194</pmid><doi>10.1016/S1473-3099(03)00517-6</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1473-3099
ispartof The Lancet infectious diseases, 2003-02, Vol.3 (2), p.87-98
issn 1473-3099
1474-4457
language eng
recordid cdi_proquest_miscellaneous_72985812
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Africa, Eastern - epidemiology
amphotericin B
Asia - epidemiology
Humans
India - epidemiology
Infectious diseases
interleukin 10
Leishmania donovani
Leishmaniasis, Cutaneous - diagnosis
Leishmaniasis, Cutaneous - epidemiology
Leishmaniasis, Cutaneous - physiopathology
Leishmaniasis, Cutaneous - therapy
Leishmaniasis, Visceral - diagnosis
Leishmaniasis, Visceral - epidemiology
Leishmaniasis, Visceral - physiopathology
Leishmaniasis, Visceral - therapy
miltefosine
Parasites
sodium stibogluconate
Sudan - epidemiology
Vector-borne diseases
title Post-kala-azar dermal leishmaniasis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A44%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Post-kala-azar%20dermal%20leishmaniasis&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Zijlstra,%20EE&rft.date=2003-02&rft.volume=3&rft.issue=2&rft.spage=87&rft.epage=98&rft.pages=87-98&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(03)00517-6&rft_dat=%3Cproquest_cross%3E72985812%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201553293&rft_id=info:pmid/12560194&rft_els_id=S1473309903005176&rfr_iscdi=true